Cd19

Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Form 6-K) (Legend Biotech Corporation)

Public Technologies 15 Jun 2026

LB2501 is an investigational, potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion.

Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, ...

Killeen Daily Herald 14 Jun 2026

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory ....

Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Legend Biotech Corporation)

Public Technologies 14 Jun 2026

) Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ... The CD19/ CD20 ...

Edit

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Lincoln Times-News 10 Jun 2026

SHANGHAI and HONG KONG, June 9, 2026 /PRNewswire/ -- Antengene ...

Edit

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases (Form 8-K) (Cullinan Therapeutics Inc)

Public Technologies 10 Jun 2026

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases ... CLN-978 triggers T cell-redirected lysis of CD19-expressing target cells in vitro and in vivo.

Edit

Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T ...

Nasdaq Globe Newswire 09 Jun 2026

Approval paves the way for CTA313 clinical study in the United States ...

Edit

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

PR Newswire 08 Jun 2026

KT209 is a novel trispecific antibody engineered to co-engage CD19, CD20, and CD3, redirecting endogenous T cells to achieve deep B-cell depletion ... KT209 is a novel CD19 x CD20 x CD3 trispecific ...

Edit

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

News-Press Now 04 Jun 2026

Company evaluating systemic ...

Edit

PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

PR Newswire 28 May 2026

Importantly, the first patient treated in this expansion phase – a patient with transformed FL (tFL) who had progressed following CD19 CAR T therapy – achieved a CR at their first disease assessment.

Edit

CD19 CAR-T Therapy Achieves Triple Remission in Refractory Autoimmune Diseases

GetNews 26 May 2026

However, recent progress in cellular engineering has introduced CD19 CAR-T cell therapy ... These engineered T cells seek out and destroy the B cell population by targeting the CD19 antigen.

Edit

Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

PR Newswire 18 May 2026

A Novel CD19 x CD3 T-Cell Engager Demonstrating Deep B-Cell Depletion and a Favorable Safety Profile in Non-Human Primates Session. New therapeutic targets in Rheumatoid Arthritis and Sjögren's Date/Time. Thursday, June 4, 2026 .

Edit

Budoprutug and the CD19 Opportunity (Climb Bio Inc)

Public Technologies 05 May 2026

Budoprutug and the CD19 Opportunity ... CD19 ... A Differentiated CD19 mAb with Broad Autoimmune Potential ... Budoprutug - anti-CD19 mAb in development for pMN, ITP, and SLE; Fast Track and Orphan Drug Designations granted for pMN ... Anti-CD19 ... Anti-CD19 ... CD19+.

Edit

Miv-cel (Mivocabtagene Autoleucel; KYV-101), CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (Kyverna Therapeutics Inc)

Public Technologies 22 Apr 2026

). The text version of this document is not available ... Attachments Permalink. Disclaimer.

Edit

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Hastings Tribune 22 Apr 2026

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s ...

Edit

Design of Phase 3 of KYSA-6, a Global, Open-Label, Randomized, Controlled Study of Miv-cel (Mivocabtagene Autoleucel; KYV-101), a Fully Human CD19 Chimeric Antigen Receptor T-Cell Therapy, Versus Ongoing Standard-of-Care Immunotherapy in Generalized Myasthenia Gravis (Kyverna Therapeutics Inc)

Public Technologies 22 Apr 2026

Anti-CD20 or -CD19 monoclonal antibodies or FcRn inhibitors not allowed as defined in inclusion criteria ... Miv-cel is a fully human autologous CD19 CAR T with CD28 costimulation designed for potency and tolerability in autoimmune diseases8,9.

Podcasts:

Latest News for: cd19

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Form 6-K) (Legend Biotech Corporation)

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, ...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Legend Biotech Corporation)

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases (Form 8-K) (Cullinan Therapeutics Inc)

Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T ...

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

CD19 CAR-T Therapy Achieves Triple Remission in Refractory Autoimmune Diseases

Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

Budoprutug and the CD19 Opportunity (Climb Bio Inc)

Miv-cel (Mivocabtagene Autoleucel; KYV-101), CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (Kyverna Therapeutics Inc)

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Design of Phase 3 of KYSA-6, a Global, Open-Label, Randomized, Controlled Study of Miv-cel (Mivocabtagene Autoleucel; KYV-101), a Fully Human CD19 Chimeric Antigen Receptor T-Cell Therapy, Versus Ongoing Standard-of-Care Immunotherapy in Generalized Myasthenia Gravis (Kyverna Therapeutics Inc)

Article Search

EXPLORE WN.com